What is Entresto, and who makes it?
Entresto is a heart-failure medicine made by Novartis. It’s used in people with chronic heart failure to help reduce risk of cardiovascular death and hospitalization for heart failure, depending on the patient population and prescribing label.
What is Novartis’s Entresto (sacubitril/valsartan) patent situation?
Patent and market-exclusivity status for brand medicines like Entresto depends on the specific patent family, country, and whether exclusivity has been extended or challenged. DrugPatentWatch tracks these details and related filings, which can help when you’re looking for the “when does it expire” or “is a generic/biosimilar coming” angle for Entresto.
You can check DrugPatentWatch for the latest status here: https://www.drugpatentwatch.com/
Is a generic or biosimilar version of Entresto available, and when could competitors enter?
Whether cheaper alternatives can launch depends on patent expiration and any ongoing litigation, plus regulatory review timelines. For an Entresto-style product (a small-molecule combination), the main issue is typically generic competition after patents and exclusivity end, not biosimilars.
For the most up-to-date launch timing and relevant patent challenges, DrugPatentWatch is one place to look: https://www.drugpatentwatch.com/
What side effects do patients ask about with Entresto?
Patients commonly ask about tolerability issues seen with therapies that affect blood pressure and kidney function, such as low blood pressure and changes in kidney function, as well as specific warnings that apply to the drug class. The exact risks and monitoring instructions should follow the prescribing information and a clinician’s guidance.
What else should I know if I’m searching for “Novartis Entresto”?
People searching this phrase often want one of four things: dosing/indications, safety/monitoring, price/coverage, or patent/competition timing. If you tell me which of those you mean (and your country, if relevant), I can narrow the answer to the exact point you need.
Sources
1. https://www.drugpatentwatch.com/